ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $6,456,896 | -12.2% | 60,221 | 0.0% | 0.01% | -16.7% |
Q4 2022 | $7,354,791 | +22.5% | 60,221 | +3.6% | 0.01% | +20.0% |
Q3 2022 | $6,002,000 | +26.2% | 58,127 | +13.6% | 0.01% | +42.9% |
Q2 2022 | $4,757,000 | -18.5% | 51,174 | +1.7% | 0.01% | -12.5% |
Q1 2022 | $5,836,000 | +17.4% | 50,305 | +36.2% | 0.01% | +33.3% |
Q4 2021 | $4,970,000 | -11.5% | 36,943 | +4.8% | 0.01% | -33.3% |
Q3 2021 | $5,618,000 | +87.5% | 35,248 | +54.7% | 0.01% | +125.0% |
Q2 2021 | $2,997,000 | +10.4% | 22,780 | +8.2% | 0.00% | 0.0% |
Q1 2021 | $2,714,000 | -57.1% | 21,057 | -44.4% | 0.00% | 0.0% |
Q4 2020 | $6,320,000 | +105.5% | 37,894 | +95.5% | 0.00% | -20.0% |
Q3 2020 | $3,076,000 | +17.3% | 19,388 | +9.4% | 0.01% | 0.0% |
Q2 2020 | $2,622,000 | +52.4% | 17,729 | +21.9% | 0.01% | +25.0% |
Q1 2020 | $1,720,000 | -14.7% | 14,538 | +0.3% | 0.00% | +33.3% |
Q4 2019 | $2,016,000 | +44.6% | 14,492 | 0.0% | 0.00% | +50.0% |
Q3 2019 | $1,394,000 | – | 14,492 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |